DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating)'s stock price dropped 0.4% on Thursday . The stock traded as low as $9.95 and last traded at $9.95. Approximately 200 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 150,712 shares. The stock had previously closed at $9.99.
DA32 Life Science Tech Acquisition Stock Down 0.4 %
The company's fifty day moving average price is $9.89 and its two-hundred day moving average price is $9.79.
Get DA32 Life Science Tech Acquisition alerts:Institutional Trading of DA32 Life Science Tech Acquisition
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Karpus Management Inc. acquired a new stake in shares of DA32 Life Science Tech Acquisition in the third quarter valued at about $525,000. Mangrove Partners lifted its stake in shares of DA32 Life Science Tech Acquisition by 513.4% in the third quarter. Mangrove Partners now owns 450,000 shares of the company's stock valued at $4,379,000 after purchasing an additional 376,644 shares during the period. Cantor Fitzgerald L. P. lifted its stake in shares of DA32 Life Science Tech Acquisition by 69.0% in the third quarter. Cantor Fitzgerald L. P. now owns 278,587 shares of the company's stock valued at $2,711,000 after purchasing an additional 113,753 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of DA32 Life Science Tech Acquisition by 216.1% in the third quarter. Cubist Systematic Strategies LLC now owns 445,410 shares of the company's stock valued at $4,334,000 after purchasing an additional 304,492 shares during the period. Finally, Exos TFP Holdings LLC acquired a new stake in shares of DA32 Life Science Tech Acquisition in the third quarter valued at about $737,000. Institutional investors and hedge funds own 60.57% of the company's stock.
About DA32 Life Science Tech Acquisition
(Get Rating)DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
Featured Stories
- Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.